UCB chases after Argenx with FcRN drug for myasthenia gravisUCB has the positive result it was hoping for in its phase 3 trial of anti-neonatal FC receptor Share XUCB chases after Argenx with FcRN drug for myasthenia gravishttps://pharmaphorum.com/news/ucb-chases-after-argenx-with-fcrn-drug-for-myasthenia-gravis/
Novartis takes aim at risky Parkinson’s target with $1.5bn UCB dealNovartis has licensed a potential drug for Parkinson’s from Belgium’s UCB that it thinks could be the first Share XNovartis takes aim at risky Parkinson’s target with $1.5bn UCB dealhttps://pharmaphorum.com/news/novartis-takes-aim-at-risky-parkinsons-target-with-1-5bn-ucb-deal/
Pharma group will develop ‘digital endpoint’ for atopic dermatitisThe development of digital medicine requires valid endpoints that can be used in clinical trials, and a consortium Share XPharma group will develop ‘digital endpoint’ for atopic dermatitishttps://pharmaphorum.com/news/pharma-group-will-develop-digital-endpoint-for-atopic-dermatitis/
UCB licenses AI tech for spinal fracture detection to ImageBiopsyAn artificial intelligence-based tool for identifying hard-to-detect spinal fractures, developed by Belgian drugmaker UCB, has been licensed out Share XUCB licenses AI tech for spinal fracture detection to ImageBiopsyhttps://pharmaphorum.com/news/ucb-licenses-ai-tech-for-spinal-fracture-detection-to-imagebiopsy/
IL-17 tailender UCB gets EU OK for bimekizumab in psoriasisUCB has been bringing up the rear in the IL-17 inhibitor category with bimekizumab, but now has EU Share XIL-17 tailender UCB gets EU OK for bimekizumab in psoriasishttps://pharmaphorum.com/news/il-17-tailender-ucb-gets-eu-ok-for-bimekizumab-in-psoriasis/
AZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialIt has only been a month since AstraZeneca’s $39 billion takeover of Alexion was completed, but the new Share XAZ’s Alexion plans hit a snag as Ultomiris flunks ALS trialhttps://pharmaphorum.com/news/azs-alexion-takeover-hits-a-snag-as-ultomiris-flunks-als-trial/
UCB’s bimekizumab ‘pre-approved’ using NICE fast-track schemeUCB’s bimekizumab hasn’t been approved for marketing in Europe yet, but has already been given the nod for Share XUCB’s bimekizumab ‘pre-approved’ using NICE fast-track schemehttps://pharmaphorum.com/news/ucbs-bimekizumab-pre-approved-using-nice-fast-track-scheme/
UCB and Microsoft announce digital drug R&D tie-upUCB and Microsoft have announced a multi-year strategic collaboration to advance the digitalisation of the Belgian pharma company Share XUCB and Microsoft announce digital drug R&D tie-uphttps://pharmaphorum.com/news/ucb-and-microsoft-announce-digital-drug-rd-tie-up/
UCB backs epilepsy-focused digital heath startup Nile AIBelgian drugmaker UCB has been steadily building its digital health expertise for several years, and that includes nurturing Share XUCB backs epilepsy-focused digital heath startup Nile AIhttps://pharmaphorum.com/news/ucb-backs-epilepsy-focused-digital-heath-startup-nile-ai/
